Risdiplam is a highly potent SMN2 splicing modifier that increases exon 7 inclusion in SMN2 mRNA transcripts in in vitro assays and in transgenic mouse models of SMA [95,96,97]. Here, SMN2 is linked to proximal spinal muscular atrophy.